Exhibit 10.5

 

CONSENT AND WARRANT EXCHANGE AGREEMENT

 

This CONSENT AND WARRANT EXCHANGE AGREEMENT (this “Agreement”) is made effective as of November 15, 2026, by and between Q/C Technologies, Inc. (the “Company”) and PharmaCyte Biotech, Inc. (the “Holder”), in its capacity as the holder of the Warrants (as defined below) and of the Holder Series H Shares (as defined below).

 

RECITALS

 

WHEREAS, on May 20, 2024, the Company entered into a Securities Purchase Agreement (the “Series G Purchase Agreement”), pursuant to which the Company sold long-term warrants (the “Series G Long-Term Warrants”) to acquire up to 3,854,626 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”);

 

WHEREAS, the Holder acquired and is the record and beneficial owner of 2,076,351 Series G Long-Term Warrants (the “Warrants”);

 

WHEREAS, the Company has outstanding shares of its Series H Convertible Preferred Stock, par value $0.001 per share (the “Series H Preferred Stock”), issued pursuant to the Certificate of Designations of Series H Convertible Preferred Stock filed with the Secretary of State of the State of Delaware, dated September 1, 2025, as amended by the Certificate of Amendment thereto dated October 3, 2025 (as amended, the “Series H Certificate of Designations”), which provides for a “Maturity Date” (as defined therein) of March 2, 2027, and which may be amended with the vote or written consent of the Required Holders (as defined in the Series H Certificate of Designations), voting separately as a single class;

 

WHEREAS, the Holder is the record and beneficial owner of 3,000,000 shares of Series H Preferred Stock (the “Holder Series H Shares”), which constitute more than a majority of the outstanding shares of Series H Preferred Stock and, accordingly, the Required Holders; and

 

WHEREAS, the Company and the Holder have agreed to enter into this Agreement pursuant to which, subject to satisfaction or waiver of the conditions to Closing (as defined below) and the other terms of this Agreement, (i) 851,304 Series G Long-Term Warrants (collectively, the “Exchange Warrants”) and the rights and obligations of the Holder thereunder will be exchanged for 4,982,272 shares of Common Stock (the “Shares”), with all Warrants other than the Exchange Warrants remaining outstanding in accordance with their terms, and (ii) the Holder, as a holder of Series H Preferred Stock, will consent to the extension of the Maturity Date of the Series H Preferred Stock by six (6) months, as set forth in Section 1.03.

 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, intending to be legally bound, the parties hereto agree as follows:

 

 
 

 

AGREEMENT

 

ARTICLE I. EXCHANGE

 

1.01 The Exchange. At the Closing (as defined below), the Company and the Holder shall, pursuant to Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”), exchange the Exchange Warrants for the Shares (the “Exchange”), as described herein.

 

(a) Closing. Subject to the satisfaction (or waiver by the Holder in its sole discretion) of the conditions set forth in Section 1.02 and the other terms of this Agreement, the closing of the Exchange (the “Closing”) shall occur remotely upon, and shall be deemed to occur simultaneously with, the actual delivery of all of the Shares to the Holder or its designee in accordance with Section 1.01(c) (the date of such delivery, the “Closing Date”). The Holder shall not be required to surrender or deliver the Exchange Warrants before the Shares have been actually delivered to the Holder or its designee as provided herein. The Company’s delivery of the Shares and the Holder’s surrender or deemed surrender of the Exchange Warrants are concurrent conditions to the effectiveness of the Exchange and cancellation of the Exchange Warrants, and no Exchange Warrant shall be deemed surrendered, cancelled or extinguished before such actual delivery. The Holder acknowledges that immediately following the Exchange, the Holder is deemed an “affiliate” of the Company, as such term is defined in Rule 144(a)(1) promulgated under the Securities Act.

 

(b) Consideration. At the Closing, the Shares shall be issued to Holder solely in exchange for the Exchange Warrants, without payment of any additional consideration by such Holder that would not be consistent with the application of Section 3(a)(9) of the Securities Act. Notwithstanding anything to the contrary, the Company’s obligations under the Exchange Warrants shall not be terminated, cancelled or waived, and no Exchange Warrant shall be deemed surrendered or extinguished, until Holder has actually received all Shares required under this Agreement. Upon such actual receipt, the Exchange Warrants shall be deemed surrendered and cancelled, and Holder shall deliver or cause to be delivered the original Exchange Warrants in accordance with Section 1.01(c); this Section 1.01(b) shall constitute an instrument of termination and cancellation effective upon such actual receipt, without affecting any claim or remedy arising before or from the Company’s failure to perform this Agreement.

 

(c) Delivery. The Company shall deliver or cause its transfer agent (the “Transfer Agent”) to deliver the Shares to Holder or its designee in certificated or other book-entry form no later than two (2) business days after the date on which the conditions set forth in Section 1.02 have been satisfied (or waived by the Holder), and such delivery shall constitute the Closing. Prior to such delivery, the Company shall deliver an irrevocable instruction letter to the Transfer Agent, acknowledged by the Transfer Agent, directing the issuance, delivery, and holding-period tacking contemplated by this Agreement, and the Company shall bear all reasonable transfer-agent, legal-opinion, and other costs of issuance and delivery. The Holder shall deliver or cause to be delivered to the Company (or its designee), within five (5) trading days after Holder’s actual receipt of all Shares, the original Exchange Warrants.

 

(d) Tacking. The holding period of the Shares for purposes of Rule 144 and Section 4(a)(1) of the Securities Act tacks on to the holding period of the Exchange Warrants.

 

(e) Other Documents. The Company and the Holder shall execute and/or deliver such other documents and agreements as are reasonably necessary to effectuate the Exchange pursuant to the terms of this Agreement.

 

 
 

 

1.02 Conditions to Holder’s Closing Obligation. The Holder’s obligation to consummate the Exchange, including its obligation to surrender the Exchange Warrants, is subject to the satisfaction (or waiver by the Holder in its sole discretion) on or before the Closing of each of the following conditions:

 

(a) The Company shall have executed and delivered this Agreement and all other documents required hereunder, including the irrevocable instruction letter to the Transfer Agent specified in Section 1.01(c).

 

(b) The representations and warranties of the Company shall be true and correct in all material respects as of the Closing, and the Company shall have performed in all material respects all covenants and obligations required to be performed at or before the Closing.

 

(c) The Shares shall have been approved for listing on The Nasdaq Stock Market LLC (“Nasdaq”) (or the principal Nasdaq market on which the Common Stock is then listed), subject only to official notice of issuance, and trading of the Common Stock shall not have been suspended or threatened in writing with suspension by Nasdaq or the Securities and Exchange Commission (the “SEC”).

 

(d) No law, order or injunction shall prohibit the Exchange, and no event shall have occurred since the date hereof that has materially impaired, or would reasonably be expected to materially impair, the Company’s ability to issue, deliver, list or permit the transfer of the Shares or perform its obligations under this Agreement.

 

1.03 Maturity Date Extension. The Holder, in its capacity as the holder of the Holder Series H Shares and for purposes of Section 32(b) of the Series H Certificate of Designations and Section 228 of the Delaware General Corporation Law (the “DGCL”), hereby irrevocably consents to, approves and adopts amending and restating Section 33(jj) of the Series H Certificate of Designations to read:

 

“Maturity Date” shall mean September 2, 2027; provided, however, the Maturity Date may be extended upon the mutual consent of a Holder and the Company with respect to such Holder; and provided further, however, the Maturity Date may be extended at the option of a Holder with respect to such Holder (i) in the event that, and for so long as, a Triggering Event shall have occurred and be continuing or any event shall have occurred and be continuing that with the passage of time and the failure to cure would result in a Triggering Event or (ii) through the date that is twenty (20) Business Days after the consummation of a Fundamental Transaction in the event that a Fundamental Transaction is publicly announced or a Change of Control Notice is delivered prior to the Maturity Date, provided further that if a Holder elects to convert some or all of its Preferred Shares pursuant to Section 4 hereof, and the Conversion Amount would be limited pursuant to Section 4(d) hereunder, the Maturity Date shall automatically be extended until such time as such provision shall not limit the conversion of such Preferred Shares.

 

Such consent shall constitute the written consent without a meeting of the Required Holders, voting separately as a single class (the “Required Holder Consent”).

 

 
 

 

1.04 Demand Registration Rights. The Company shall, upon Holder’s written demand made at any time after ninety (90) days following the Closing (the “Demand”), promptly, and in any event within thirty (30) days after receipt of the Demand, file with the SEC a registration statement covering the resale by Holder of all Shares then held by Holder (the “Registration Statement”), and shall use commercially reasonable efforts to cause the Registration Statement to become effective as soon as practicable after such filing and to remain effective and available for use continuously until the earlier of (A) the date on which all Shares covered by the Registration Statement have been sold or (B) the date on which all such Shares may be sold by Holder pursuant to Rule 144 under the Securities Act (or any successor rule thereto), without any requirement that the Company comply with Rule 144(c) (or any successor provision) and without any volume, manner-of-sale, or current public information limitations; provided that the Company shall promptly prepare and file with the SEC such amendments and supplements to the Registration Statement and the related prospectus as may be necessary to keep the Registration Statement effective and available for use throughout and to comply with applicable securities laws. The Company shall promptly notify Holder in writing (i) when the Registration Statement is filed and when it is declared effective, (ii) of any request by the SEC for an amendment or supplement to the Registration Statement or related prospectus or for additional information, (iii) of the issuance by the SEC of any stop order or the initiation of any proceeding for that purpose, (iv) of any event that causes the Registration Statement or related prospectus to contain an untrue statement of a material fact or omit a material fact necessary to make the statements therein not misleading, and (v) of any suspension of the use of the Registration Statement permitted below and the date on which such suspension ends, and shall promptly furnish Holder with copies of all such amendments, supplements, and notices. The Company may suspend the use of the Registration Statement only (A) if the Company’s board of directors determines in good faith that continued use would require disclosure of material non-public information that would be materially prejudicial to the Company or its stockholders or would materially interfere with a bona fide material financing, acquisition, or similar corporate transaction, or (B) to the extent required by applicable securities laws or an SEC stop order; provided that any suspension under clause (A) shall be for the shortest period reasonably necessary and shall not exceed thirty (30) consecutive days or, in the aggregate, sixty (60) days in any twelve-month period, and no more than two (2) suspensions under clause (A) may occur in any twelve-month period. During any permitted suspension, the Company shall use commercially reasonable efforts to terminate the suspension as soon as practicable, and Holder may continue to sell Shares pursuant to Rule 144 or another available exemption. Upon receipt of a notice of a permitted suspension, Holder shall discontinue use of the Registration Statement until receipt of written notice from the Company that use may resume, and the Company shall promptly notify Holder when the Registration Statement is again available for use. The Company shall bear all reasonable out-of-pocket expenses incident to the registration contemplated hereby, including SEC and FINRA filing fees, Nasdaq listing fees, printing and distribution expenses, fees and disbursements of the Company’s counsel and independent public accountants, and the reasonable fees and disbursements of one counsel selected by Holder. The Company shall indemnify, defend, and hold harmless Holder, its directors, officers, partners, members, employees, agents, and representatives, and each person, if any, who controls Holder within the meaning of the Securities Act, from and against any loss, claim, damage, liability, cost, or expense (including reasonable attorneys’ fees and disbursements) arising out of or based upon (A) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, any related prospectus, or any amendment or supplement thereto, or (B) any omission or alleged omission to state therein a material fact required to be stated or necessary to make the statements therein not misleading, except, in each case, to the extent that such loss, claim, damage, liability, cost, or expense results from information furnished in writing by Holder expressly for use therein; provided that the Company shall not be liable to the extent that any such loss, claim, damage, liability, cost, or expense results from Holder’s failure to deliver a current prospectus after the Company has furnished Holder with a corrected or supplemented prospectus. Holder shall indemnify, defend, and hold harmless the Company, its directors, officers, agents, and representatives, and each person, if any, who controls the Company within the meaning of the Securities Act, from and against any loss, claim, damage, liability, cost, or expense arising out of or based upon any untrue statement or omission in the Registration Statement or related prospectus to the extent, but only to the extent, that such statement or omission was made in reliance upon and in conformity with information furnished in writing by Holder expressly for use therein; provided that Holder’s liability under this sentence shall not exceed the net proceeds received by Holder from sales pursuant to the Registration Statement. The rights and obligations set forth in this subsection shall survive the Closing and the surrender or cancellation of the Exchange Warrants.

 

 
 

 

ARTICLE II. REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

The Company represents and warrants to Holder as of the date hereof as follows:

 

2.01 Organization, Good Standing and Power. The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware and has the requisite corporate power to own, lease and operate its properties and assets and to conduct its business as it is now being conducted.

 

2.02 Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and perform this Agreement and to issue the Shares in accordance with the terms hereof. The execution, delivery and performance of this Agreement by the Company and the consummation by it of the transactions contemplated hereby have been duly and validly authorized by all necessary corporate action of the Company, and no further consent or authorization of the Company or its board of directors or stockholders is required, other than, with respect to the Series H Amendment, the Series H Resolutions and the Required Holder Consent described in Section 1.03 and Section 2.06. When executed and delivered by the Company, this Agreement shall constitute a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application.

 

2.03 Issuance of Shares. When the Shares are issued and delivered in accordance with the terms of this Agreement, the Shares shall be duly authorized, validly issued, fully paid and non-assessable, free and clear of all liens, claims, security interests and other encumbrances, and free of any pre-emptive, participation, rights of first refusal or similar rights. The Company shall have reserved sufficient authorized and unissued Common Stock for the issuance and delivery of the Shares.

 

2.04 No Conflicts. The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company’s certificate or articles of incorporation, bylaws or other organizational or charter documents; or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any liens, claims, security interests, other encumbrances or defects upon any of the properties or assets of the Company in connection with, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material understanding to which such Company is a party or by which any property or asset of the Company is bound or affected; or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected, except, in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a material adverse effect upon the business, prospects, properties, operations, condition (financial or otherwise) or results of operations of the Company, taken as a whole, or in its ability to perform its obligations under this Agreement.

 

2.05 Nasdaq Listing. The Company represents, warrants and covenants that it has taken, and will continue to take, all actions and make all filings necessary to cause the Shares to be approved for listing on Nasdaq, subject to official notice of issuance, to remain listed following the Closing. The Company shall promptly notify Holder of any notice of suspension, delisting or threatened suspension or delisting of the Common Stock or any refusal by Nasdaq to approve listing of the Shares.

 

 
 

 

2.06 Series H Amendment. The special committee of the Company’s board of directors, composed solely of directors who are disinterested with respect to the transactions contemplated hereby (the “Special Committee”), has duly adopted resolutions (the “Series H Resolutions”) approving and declaring advisable a certificate of amendment to the Series H Certificate of Designations amending and restating Section 33(jj) thereof as set forth in Section 1.03 (the “Series H Amendment”), and such resolutions are in full force and effect and have not been rescinded or modified. Upon the Required Holder Consent, the Series H Amendment has been duly approved in accordance with Section 242 of the DGCL, the Company’s certificate of incorporation and Section 32(b) of the Series H Certificate of Designations, and no other vote or consent of the holders of any class or series of the Company’s capital stock is required. The Company will file the Series H Amendment with the Secretary of State of the State of Delaware within four (4) business days after the date hereof and will provide prompt notice of such action to the holders of Series H Preferred Stock that did not consent in writing as required by Section 228(e) of the DGCL. Upon such filing, the Series H Amendment will be effective, and the Maturity Date of the Series H Preferred Stock will be September 2, 2027. The Closing and the Exchange are not conditioned on the Series H Amendment, and no additional consideration shall be paid by the Holder in respect of the Series H Amendment.

 

ARTICLE III. REPRESENTATIONS AND WARRANTIES OF THE HOLDER

 

The Holder represents and warrants to the Company as of the date hereof as follows:

 

3.01 Organization and Standing of the Holder. Holder is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization.

 

3.02 Authorization and Power. Holder has the requisite power and authority to enter into and perform this Agreement. The execution, delivery and performance of this Agreement by Holder and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary corporate action, and no further consent or authorization of Holder or its board of directors or stockholders is required. When executed and delivered by Holder, this Agreement shall constitute the valid and binding obligations of Holder enforceable against Holder in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application.

 

3.03 Ownership of Holder Series H Shares. Holder is the record and beneficial owner of the Holder Series H Shares, which constitute a majority of the outstanding shares of Series H Preferred Stock, free and clear of any voting agreement, proxy or other restriction that would prevent Holder from delivering the consent set forth in Section 1.03.

 

ARTICLE IV. MISCELLANEOUS

 

4.01 Amendment. No provision of this Agreement may be waived or amended except in a written instrument signed by the Company and Holder.

 

 
 

 

4.02 Notices. Any notice, demand, request, waiver or other communication required or permitted to be given hereunder shall be in writing and shall be effective (a) upon hand delivery by telecopy or facsimile at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur or (c) upon delivery by e-mail (if delivered on a business day during normal business hours where such notice is to be received) upon recipient’s actual receipt and acknowledgement of such e-mail. The addresses for such communications shall be:

 

If to the Company:

 

Q/C Technologies, Inc.

333 Bush Street, Suite 1400

San Francisco, CA 94104

Attn: Joshua Silverman

Title: Chief Executive Officer

 

If to the Holder:

 

PharmaCyte Biotech, Inc.

3960 Howard Hughes Parkway, Suite 500

Las Vegas, NV, 89169

Attn: Carlos Trujillo

Title: Chief Financial Officer

 

Any party hereto may from time to time change its address for notices by giving written notice of such changed address to the other party hereto.

 

4.03 Waivers. No waiver by either party of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right accruing to it thereafter.

 

4.04 Survival. All representations, warranties, covenants and agreements of the Company under this Agreement shall survive the Closing and the surrender or cancellation of the Exchange Warrants and remain in effect until fully performed or satisfied.

 

4.05 Headings. The article, section and subsection headings in this Agreement are for convenience only and shall not constitute a part of this Agreement for any other purpose and shall not be deemed to limit or affect any of the provisions hereof.

 

4.06 Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York, without giving effect to any of the conflicts of law principles that would result in the application of the substantive law of another jurisdiction.

 

4.07 Counterparts. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and shall become effective when counterparts have been signed by each party and delivered to the other parties hereto, it being understood that all parties need not sign the same counterpart. Signature pages to this Agreement may be delivered by facsimile or other means of electronic transmission.

 

[Signature Page Follows.]

 

 
 

 

IN WITNESS WHEREOF, the parties hereto have caused this Consent and Warrant Exchange Agreement to be duly executed by their respective authorized officers as of the date first above written.

 

  COMPANY:
     
  Q/C TECHNOLOGIES, INC.
     
  By: /s/ Todd Fagan
  Name: Todd Fagan
  Title: Chief Financial Officer

 

[Signature page to Consent and Warrant Exchange Agreement]

 

 
 

 

HOLDER:  
     
PHARMACYTE BIOTECH, INC.  
     
By: /s/ Carlos Trujillo  
Name: Carlos Trujillo  
Title: Chief Financial Officer